BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia

Oncotarget
Valérie VidalThomas Cluzeau

Abstract

Azacitidine (AZA), the reference treatment for most higher-risk myelodysplastic (MDS) patients can also improve overall survival (OS) in elderly acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy, but reliable biological markers predicting response and OS in patients treated with AZA are lacking. In a preliminary study, we found that an increase of the percentage of BCL2L10, an anti-apoptotic member of the bcl-2 family, was correlated with AZA resistance. In this study, we assessed prospectively by flow cytometry the prognostic value of BCL2L10 positive bone marrow mononuclear cells in 70 patients (42 MDS and 28 AML), prior to AZA treatment.In patients with baseline marrow blasts below 30%, the baseline percentage of bone marrow BCL2L10 positive cells inversely correlated with response to AZA and OS independently of the International Prognostic Scoring System (IPSS) and IPSS-revised (IPSS-R). Specifically, OS was significantly lower in patients with more than 10% BCL2L10 positive cells (median 8.3 vs 22.9 months in patients with less than 10% positivity, p = 0,001). In summary, marrow BCL2L10 positive cells may be a biomarker for azacitidine response and OS, with a potential impact in clinical practice.

References

Mar 30, 2001·The Journal of Biological Chemistry·N KeJ C Reed
Aug 19, 2003·The Biochemical Journal·Dayong ZhaiJohn C Reed
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Feb 20, 2004·Cancer Research·Kohichiroh YasuiJohji Inazawa
Jan 12, 2012·Proceedings of the National Academy of Sciences of the United States of America·Levi J BeverlyHarold Varmus
Apr 10, 2014·British Journal of Haematology·Amer M ZeidanUNKNOWN Eastern Cooperative Oncology Group (ECOG) and North American Leukemia intergroup
Mar 31, 2015·The Journal of Clinical Investigation·Kristen MeldiMaria E Figueroa

❮ Previous
Next ❯

Citations

Dec 8, 2017·American Journal of Hematology·Guillermo Montalban-Bravo, Guillermo Garcia-Manero
Aug 4, 2020·Cancer Biomarkers : Section a of Disease Markers·Yangli ZhaoJingdong Zhou
Jun 4, 2019·Therapeutic Advances in Hematology·Angela Gil-Perez, Guillermo Montalban-Bravo

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
MDS

Clinical Trials Mentioned

NCT01210274

Software Mentioned

SPSS

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.